Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes

Blood

Volumn 120, Issue 26, 2012, Pages 5181-5184

  Giulino Roth, Lisa ^a,b   Wang, Kai ^c   MacDonald, Theresa Y ^b   Mathew, Susan ^b   Tam, Yifang ^b   Cronin, Maureen T ^c   Palmer, Gary ^c   Lucena Silva, Norma ^d   Pedrosa, Francisco ^d   Pedrosa, Marcia ^d   Teruya Feldstein, Julie ^a   Bhagat, Govind ^e   Alobeid, Bachir ^e   Leoncini, Lorenzo ^f   Bellan, Cristiana ^f   Rogena, Emily ^g   Pinkney, Kerice A ^e   Rubin, Mark A ^b   Ribeiro, Raul C ^h   Yelensky, Roman ^c   Tam, Wayne ^b   Stephens, Philip J ^c   Cesarman, Ethel ^b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c FOUNDATION MEDICINE   (United States)

^d INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^e NewYork Presbyterian Hospital   (United States)

^f UNIVERSITY OF SIENA   (Italy)

^g UNIVERSITY OF NAIROBI   (Kenya)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; K RAS PROTEIN; MYC PROTEIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL TRANSFORMATION; CHILD; CHILDHOOD CANCER; CHROMATIN; EPIDEMIOLOGY; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE INSERTION; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HAPLOINSUFFICIENCY; HUMAN; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84871498761     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-437624     Document Type: Article

References (22)

1. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-2743. (Pubitemid 46482065)
2. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-2780. (Pubitemid 46482070)
3. Cairo MS, Krailo MD, Morse M, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia. 2002;16(4):594-600. (Pubitemid 34449739)
4. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-120.
5. Lai JL, Fenaux P, Zandecki M, Nelken B, Huart JJ, Deminatti M. Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. Ann Genet. 1989;32(1):26-32. (Pubitemid 19129887)
6. Lones MA, Sanger WG, Le Beau MM, et al. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol. 2004;26(3):169-178.
7. Nelson M, Perkins SL, Dave BJ, et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol. 2010;148(4):600-610.
8. Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer. 2006;107(5):1084-1092. (Pubitemid 44291158)
9. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000;95(6):2104-2110. (Pubitemid 30151652)
10. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11(7):481-492.
11. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532- 1543.
12. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44(5):570-574.
13. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219-1223.
14. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47-59.
15. Zhou P, Levy NB, Xie H, et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood. 2001;97(12):3902-3909.
16. Zhou P, Qian L, Bieszczad CK, et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood. 1998;92(9):3226-3239. (Pubitemid 28492330)
17. Schiffman JD, Lorimer PD, Rodic V, et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol. 2011;155(4):477-486.
18. Vrana JA, Bieszczad CK, Cleaveland ES, et al. An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 2002;62(3):892-900. (Pubitemid 34126970)
19. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110-114.
20. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 2011;16(1):59-70.
21. Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104-109.
22. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945-950.